SUMMARY
Genetic epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome characterized by heterogeneous phenotypes ranging from mild disorders such as febrile seizures to epileptic encephalopathies (EEs) such as Dravet syndrome (DS). Although DS often occurs with de novo SCN1A pathogenic variants, milder GEFS+ spectrum phenotypes are associated with inherited pathogenic variants. We identified seven cases with non-EE GEFS+ phenotypes and de novo SCN1A pathogenic variants, including a monozygotic twin pair. Febrile seizures plus (FS+) occurred in six patients, five of whom had additional seizure types. The remaining case had childhood-onset temporal lobe epilepsy without known febrile seizures. Although early development was normal in all individuals, three later had learning difficulties, and the twin girls had language impairment and working memory deficits. All cases had SCN1A missense pathogenic variants that were not found in either parent. One pathogenic variant had been reported previously in a case of DS, and the remainder were novel. Our finding of de novo pathogenic variants in mild phenotypes within the GEFS+ spectrum shows that mild GEFS+ is not always inherited. SCN1A screening should be considered in patients with GEFS+ phenotypes because identification of pathogenic variants will influence antiepileptic therapy, and prognostic and genetic counseling. KEY WORDS: Genetic epilepsy with febrile seizures plus, SCN1A, De novo pathogenic variant, Febrile seizures, Dravet syndrome.
Genetic epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome characterized by heterogeneous phenotypes. The most common is febrile seizures (FS), followed by febrile seizures plus (FS+) in which febrile and afebrile tonic-clonic seizures occur in early childhood. FS or FS+ may also be accompanied by generalized or focal seizures. At the severe end of the GEFS+ spectrum lie the developmental epileptic encephalopathies, epilepsy with myoclonic-atonic seizures (MAE), and Dravet syndrome (DS). 1 The mechanisms underlying phenotypic heterogeneity within families are not understood but may involve variable expressivity of a single causative gene, modifying genes, or epigenetic factors. Pathogenic variants in SCN1A, SCN1B, SCN9A, STX1B, and GABRG2 have been associated with GEFS+ 2 ; SCN1A is the most commonly implicated gene, found in approximately 11% of large families.
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SCN1A pathogenic variants have been identified primarily in individuals with GEFS+ phenotypes in the setting of autosomal dominant families and as de novo events in the epileptic encephalopathies. 4 DS is a developmental epileptic encephalopathy (EE) that presents with febrile seizures in the first year of life followed by developmental arrest or regression and multiple types of seizures. More than 80% of patients with DS have SCN1A pathogenic variants, of which 90% occur de novo. 5 De novo SCN1A pathogenic variants are also rarely found in severe infantile EEs such as epilepsy of infancy with migrating focal seizures. 6 Here, we report seven patients with de novo SCN1A pathogenic variants causing milder GEFS+ phenotypes, illustrating that this genetic syndrome is not necessarily familial or inherited.
Methods
We reviewed our Epilepsy Genetics Research Program database to identify individuals with GEFS+ phenotypes and de novo SCN1A pathogenic variants. Patients with the EEs of DS and MAE were excluded. Individuals underwent detailed phenotyping and review of their electroencephalography (EEG) and imaging studies, where available. The biologic significance of identified variants was assessed using in silico methods.
The Human Research Ethics Committee of Austin Health approved the study (Project No. H2007/02961). Written informed consent was obtained from all participants or parents/legal guardians in the case of minors or those with intellectual disability.
Results
Seven cases were identified with a de novo SCN1A pathogenic variant, including a pair of monozygotic twins. All pathogenic variants were identified through single gene testing.
Six cases had phenotypes of FS+, together with other seizure types in five (Table 1) . These included absence (4), hemiclonic (3), and focal seizures with evolution to a bilateral tonic-clonic seizure (4). The remaining subject (case 4) had temporal lobe epilepsy with childhood onset without known febrile seizures, but had a child with FS+ (see below). Five of the patients had drug-resistant epilepsy; details of medication response for each case are given in Table 1 . Early development was normal in all cases, but five later developed learning difficulties, and the twin girls (cases 6 and 7) had language impairment and deficits in working memory on formal speech pathology assessment at age 5 years. Magnetic resonance imaging (MRI) brain studies did not show significant abnormalities in four patients.
There was no family history of seizures in the preceding generations of three probands. Case 2 had a maternal uncle with FS and the twins (cases 6 and 7) had a maternal uncle with unconfirmed FS. Two probands (cases 4 and 5) had affected children who carried the same variant (Fig. 1) . Case 4 married her maternal first cousin and had a son with refractory febrile and afebrile seizures (including tonic and focal clonic) from 2 months of age, diffuse slowing on EEG, and moderate intellectual disability. A second son had borderline intellect and febrile seizures from 12 months until 6.5 years. Case 5 had a son who had febrile seizures at 13 months and subsequently developed absence, myoclonic, and afebrile generalized tonic-clonic seizures, occasionally provoked by flashing lights. He had normal intellect at 19 years with refractory seizures.
Sanger sequencing revealed SCN1A missense pathogenic variants in all cases, which were not present in their parents. The pathogenicity of variants met criteria defined in the 2015 American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) guidelines 7 ; based primarily on being de novo, absence in the Exome Aggregation Consortium (ExAC) database, and supported by in silico predictions (Table S1 ). All pathogenic variants were novel, with the exception of case 4 (p.A104V), which was reported previously in a case of DS (Supporting Information). 8 Four pathogenic variants were located in the pore-forming regions of SCN1A (p.G329A, p.A394D, p.H1393D, p.A1429V), with one each in the Nterminal (p.A104V) and voltage sensor (p.R859H) regions (Fig. 2 ).
Discussion
Although de novo pathogenic variants are increasingly recognized as causing a wide array of EEs with devastating consequences, their role in milder epilepsies is just beginning to emerge. The prototypic EE of DS is associated with de novo SCN1A pathogenic variants in contrast to the inherited pathogenic variants found in dominant GEFS+ families. Our series of seven patients adds to previous reports of one or two cases with de novo SCN1A pathogenic variants that have phenotypes such as FS+ that fall within the GEFS+ spectrum (Tables S1 and S2 ). This suggests that de novo pathogenic variants may arise more frequently in GEFS+ phenotypes than previously appreciated.
This leads to a departure from our original concept that GEFS+ is a familial epilepsy syndrome and suggests that a family history is not essential to make a diagnosis of GEFS+, and emphasizes that GEFS+ phenotypes can be diagnosed in sporadic individuals. There are many genetic disorders that were considered to be exclusively familial until the role of de novo genetic change was identified. Familial adenomatous polyposis is an excellent example of a phenotype initially described in families, although we now know that up to 25% of identified cases are due to de novo pathogenic variants. 9 It is exciting therefore to see a range of GEFS+ phenotypes that occur due to de novo pathogenic variants. Of our seven cases, only case 5 had FS+ alone, with the remaining six having more complex phenotypes. They commonly presented with FS+ and developed afebrile absence and/or focal motor seizures. Although development was not always normal, all individuals were capable of living independently and having children of their own, if they had not done so already. Family history was negative for FS, FS+, and other GEFS+ phenotypes in most cases, although cases 2, 6, and 7 had at least possible FS in one of their parents' siblings. This suggests the presence of additional genes related to epilepsy in these families.
Inheritance may also be complicated in case 5. First, the proband had a sister with FS who was not available for genetic testing. Although the parents tested negative A, absence; ASD, autistic spectrum disorder; CAN, medical cannabis; CBZ, carbamazepine; CLB, clobazam; ETX, ethosuximide; F-EG, focal with evolution to generalized convulsions; FS, febrile seizures; FS+, febrile seizures plus; FSIQ, full-scale intelligence quotient; GF, grandfather; GTC, generalized tonic-clonic; H, hemiclonic; LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine; M, myoclonic; MRI, magnetic resonance imaging; PB, phenobarbital; Sz, seizure; TLE, temporal lobe epilepsy; TPM, topiramate; VPA, valproate; ZNS, zonisamide.
a Cases 6 and 7 are monozygotic twins.
for the SCN1A pathogenic variant, one may have had low-level mosaicism not detected by standard Sanger sequencing, and transmitted the pathogenic variant to both the proband and her sister. Further complicating matters, the proband's husband and his sister both had FS. Given that the proband's son was more severely affected, he may have inherited modifier genes from his father in addition to the maternally inherited SCN1A pathogenic variant, which contributed to his refractory phenotype. The association of mild GEFS+ phenotypes with de novo SCN1A pathogenic variants suggests that clinical testing guidelines deserve reevaluation. In 2013, the International League Against Epilepsy (ILAE) Genetics Commission confirmed the need for SCN1A testing in cases of DS, but recommended that "infants and children with GEFS+ should not be advised to undergo SCN1A testing as it will neither influence management nor provide information regarding the patient's prognosis." 10 Based on this guideline, SCN1A testing would not be indicated for the patients we have reported here.
The notion that GEFS+ management would not change with identification of an SCN1A pathogenic variant is partially based on the belief that SCN1A-associated GEFS+ is inherited in an autosomal dominant manner. This is not always the case, as illustrated by our de novo cases in which an SCN1A pathogenic variant came to light only once they had affected children (as in cases 4 and 5). Recessive inheritance has also been reported recently with homozygous SCN1A pathogenic variants in two consanguineous families, providing another instance in which a sporadic case should be tested. 11 Furthermore, the rate of parental mosaicism in cases of apparent de novo SCN1A-associated DS may be as high as 10%. 12 Mosaic parents of individuals with DS typically exhibit milder phenotypes on the GEFS+ spectrum. 13 Recognition of the potentially complex SCN1A heritability patterns in GEFS+ suggests that SCN1A testing may have significant utility across a broader spectrum of phenotypes than just DS. Patients and their families can benefit from genetic counseling. In light of these findings, we propose that SCN1A testing be considered in all individuals with FS+ or DS, as well as in familial cases consistent with GEFS+.
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